Cassava Sciences paid $40m after the SEC raised a case about alleged misleading data and misleading investors after a Phase IIb study of its Alzheimer’s drug. Image credit: Shutterstock / Tada Images ...

Throughout the world, an estimated 800 million people consider cassava root a staple part of their diet. This starchy tuber—also known as yuca, Brazilian arrowroot, and manioc—first originated in ...

For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s ...

Studies that once seemed to support the drug, simufilam, have been called into question, leading to retractions from scientific journals and resignations of top officials at Cassava Sciences ...

Goya Foods and Republican National Committee Co-Chair Lara Trump are collaborating on Hurricane Helene relief efforts. "In the face of Hurricane Helene's devastation, Goya stands united with the ...

A Yucca Valley man accused of threatening a woman at knifepoint when she confronted him over alleged sexual abuse of her 14-year-old child was arrested following a five-hour SWAT standoff ...

The president and CEO of Goya Foods was in Houston on Thursday to announce his endorsement of former President Donald Trump. Bob Unanue spoke at a Rose Garden event in the White House to announce ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

Although Nigeria is ranked number one in cassava production globally, she imported about $54,200 in cassava in 2022, becoming the 121st largest importer of cassava in the world. This was disclosed ...

A former Alzheimer’s researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its former chief executive reaching a $40 million settlement with the Securities ...

Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle charges by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. The U.S ...